GRAIL projects FDA approval for its multi-cancer early detection test in early 2027 following an advisory committee meeting this fall.
GRAIL announced plans for an FDA advisory committee meeting in the fall, targeting potential approval of its Galleri multi-cancer early detection test in the first half of 2027. The company cited recent data from PATHFINDER 2 and NHS-Galleri studies, highlighting performance, safety, and clinical utility results during its Q2 2026 earnings call.
Management emphasized regulatory progress as a key milestone, following the presentation of detailed study findings. Prior discussions with the FDA had outlined a pathway for approval, though no formal timeline had been confirmed until now. The projected 2027 approval window aligns with earlier industry expectations for next-generation diagnostic tools.
Shares of GRAIL (GRAL) showed muted reaction in after-hours trading, reflecting investor focus on long-term regulatory outcomes rather than immediate market impact.